Cue Biopharma, Inc. Net Fee Amt
Cue Biopharma, Inc. (CUE) had Net Fee Amt of $5.47 thousand as of 2026-08-11, per its S-3 filed 2026-08-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-12
- 2026-08-11: Net Fee Amt $5.47K.
- 2026-06-17: Net Fee Amt $1.88K.
- 2026-06-02: Net Fee Amt $11.58K.
- 2026-04-27: Net Fee Amt $6.07K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-11 | $5.47K S-3 · filed 2026-08-12 |
| 2026-06-17 | $1.88K S-3 · filed 2026-06-18 |
| 2026-06-02 | $11.58K S-3 · filed 2026-06-03 |
| 2026-04-27 | $6.07K S-8 · filed 2026-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |